COMMUNIQUÉS West-GlobeNewswire

BIO-Europe C-Suite Survey: Biopharma dealmaking set to accelerate, but investor caution still caps ambition
07/10/2026
75% of biopharma leaders expect partnering and M&A appetite to increase over the next 12 months, none expect a decline 69% expect access to capital to improve, yet 79% identify investor risk aversion as the biggest [...]
Virbac : Declaration of the number of shares et voting rights 09/2026
07/10/2026
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 09/2026
07/10/2026
DÉCLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
PulseSight presents PST-611 Phase I new early clinical efficacy data at EURETINA, offering a potential breakthrough approach to treat Dry AMD/Geographic Atrophy
07/10/2026
PARIS, Oct. 07, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical-stage biotech company developing disruptive non-viral vectorized gene therapies with minimally invasive delivery technology [...]
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
07/10/2026
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 -- [...]
125,000 Orion Corporation A shares converted into B shares
07/10/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 7 OCTOBER 2026 at 9.00 EEST 125,000 Orion Corporation A shares converted into B shares In accordance with [...]
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
07/10/2026
Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 -- [...]
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
07/10/2026
First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given [...]
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
07/10/2026
SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 [...]
OGRD Alliance Advances PLPC Multi-Asset Platform Following APHELAR Milestone, Expanding Licensing and Strategic Capital Frameworks
07/10/2026
DUBAI, United Arab Emirates, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Microdomain Science connects differentiated assets across personalized immuno-oncology, acellular biotechnology, MedTech and precision nutrition as OGRD [...]
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
06/10/2026
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support [...]
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
06/10/2026
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support [...]
Monthly information on share capital and company voting rights
06/10/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
06/10/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 oct. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Merit Medical Systems to Announce Third Quarter 2026 Results on October 29, 2026
06/10/2026
SOUTH JORDAN, Utah, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that it will release its financial results for the quarter [...]
SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim
06/10/2026
SRX to dividend ETF holdings to shareholders Initial ETF to feature an actively managed digital asset hedging strategy powered by EMJX’s proprietary AI technology NORTH PALM BEACH, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE [...]
Crescent Biopharma Announces Grants of Inducement Awards
06/10/2026
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Inventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026
06/10/2026
Preclinical data showed that balanced PPARα, PPARδ and PPARγ activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesis Preclinical data [...]
Inventiva présentera plusieurs abstracts scientifiques lors de l’AASLD The Liver Meeting® 2026
06/10/2026
Des données précliniques montrent que l’activation équilibrée des trois isoformes PPARα, PPARδ et PPARγ par le lanifibranor agit sur des voies complémentaires au sein de plusieurs populations cellulaires hépatiques [...]

Pages